152 related articles for article (PubMed ID: 10412785)
1. Fluvastatin and low-density lipoprotein oxidation in hypercholesterolemic renal transplant patients.
Martínez-Castelao A; Grinyó JM; Fiol C; Castiñeiras MJ; Hurtado I; Gil-Vernet S; Serón D; Porta I; Miñarro A; Villarroya A; Alsina J
Kidney Int Suppl; 1999 Jul; 71():S231-4. PubMed ID: 10412785
[TBL] [Abstract][Full Text] [Related]
2. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine.
Holdaas H; Hartmann A; Stenstrøm J; Dahl KJ; Borge M; Pfister P
Am J Cardiol; 1995 Jul; 76(2):102A-106A. PubMed ID: 7604781
[TBL] [Abstract][Full Text] [Related]
3. A preliminary report of the safety and efficacy of fluvastatin for hypercholesterolemia in renal transplant patients receiving cyclosporine.
Goldberg RB; Roth D
Am J Cardiol; 1995 Jul; 76(2):107A-109A. PubMed ID: 7604782
[TBL] [Abstract][Full Text] [Related]
4. Effects of fluvastatin on hyperlipidemia after renal transplantation: influence of steroid therapy.
Austen JL; Shifrin FA; Bartucci MR; Knauss TC; Schulak JA; Hricik DE
Ann Pharmacother; 1996 Dec; 30(12):1386-9. PubMed ID: 8968448
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of treatment with low-dose fluvastatin in hypercholesterolemic renal transplant recipients.
Akiyama T; Ishii T; Imanishi M; Nishioka T; Matsuura T; Kurita T
Transplant Proc; 2001 May; 33(3):2115-8. PubMed ID: 11377469
[No Abstract] [Full Text] [Related]
6. Impact of fluvastatin on hyperlipidemia after renal transplantation.
Tokumoto T; Tanabe K; Ishida H; Shimmura H; Ishikawa N; Goya N; Akiba T; Toma H
Transplant Proc; 2004 Sep; 36(7):2141-4. PubMed ID: 15518777
[TBL] [Abstract][Full Text] [Related]
7. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.
Broyles FE; Walden CE; Hunninghake DB; Hill-Williams D; Knopp RH
Am J Cardiol; 1995 Jul; 76(2):129A-135A. PubMed ID: 7604788
[TBL] [Abstract][Full Text] [Related]
8. The effect of fluvastatin of hyperlipidemia in renal transplant recipients: a prospective, placebo-controlled study.
Türk S; Yildiz A; Tükek T; Akkaya V; Aras U; Türkmen A; Uras AR; Sever MS
Int Urol Nephrol; 2001; 32(4):713-6. PubMed ID: 11989571
[TBL] [Abstract][Full Text] [Related]
9. Treatment of hypercholesterolemia with fluvastatin in kidney transplant patients.
Melchor JL; Gracida C
Transplant Proc; 1998 Aug; 30(5):2054. PubMed ID: 9723390
[No Abstract] [Full Text] [Related]
10. Combined treatment of hypercholesterolemia of renal transplant allograft recipients with fluvastatin and gemfibrozil.
Vergoulas G; Miserlis G; Solonaki F; Imvrios G; Gakis D; Papanikolaou V; Papagiannis A; Visvardis G; Takoudas D; Antoniadis A
Transpl Int; 2000; 13 Suppl 1():S64-7. PubMed ID: 11111964
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A.
Park JW; Siekmeier R; Lattke P; Merz M; Mix C; Schüler S; Jaross W
J Cardiovasc Pharmacol Ther; 2001 Oct; 6(4):351-61. PubMed ID: 11907637
[TBL] [Abstract][Full Text] [Related]
12. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL.
Hussein O; Schlezinger S; Rosenblat M; Keidar S; Aviram M
Atherosclerosis; 1997 Jan; 128(1):11-8. PubMed ID: 9051193
[TBL] [Abstract][Full Text] [Related]
13. Fluvastatin in renal transplantation.
Hadjigavriel M; Kyriakides G
Transplant Proc; 1997 Nov; 29(7):3050. PubMed ID: 9365661
[No Abstract] [Full Text] [Related]
14. Effect of fluvastatin on lipoprotein profiles in treating renal transplant recipients with dyslipoproteinemia.
Li PK; Mak TW; Chan TH; Wang A; Lam CW; Lai KN
Transplantation; 1995 Oct; 60(7):652-6. PubMed ID: 7570971
[TBL] [Abstract][Full Text] [Related]
15. Changes in plasma apolipoprotein B-containing lipoparticle levels following therapy with fluvastatin and cholestyramine. European Fluvastatin Study Group.
Bard JM; Ose L; Hagen E; Duriez P; Pfister P; Fruchart JC; Dallongeville J
Am J Cardiol; 1995 Jul; 76(2):65A-70A. PubMed ID: 7604802
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the effect of two HMG CoA reductase inhibitors on LDL susceptibility to oxidation.
Portal VL; Moriguchi EH; Vieira J; Schio S; Mastalir ET; Buffé F; Bortolini EB; Brüch RS; Rodrigues R
Arq Bras Cardiol; 2003 Feb; 80(2):156-61, 150-5. PubMed ID: 12640509
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of fluvastatin, a totally synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. FLUENT Study Group. Fluvastatin Long-Term Extension Trial.
Zavoral JH; Haggerty BJ; Winick AG; Bergmann SD
Am J Cardiol; 1995 Jul; 76(2):37A-40A. PubMed ID: 7604795
[TBL] [Abstract][Full Text] [Related]
18. Effects of fluvastatin on lipid profile and apolipoproteins in Chinese patients with hypercholesterolemia.
Tomlinson B; Mak TW; Tsui JY; Woo J; Shek CC; Critchley JA; Masarei JR
Am J Cardiol; 1995 Jul; 76(2):136A-139A. PubMed ID: 7604789
[TBL] [Abstract][Full Text] [Related]
19. Fluvastatin in severe hypercholesterolemia: analysis of a clinical trial database.
Peters TK
Am J Cardiol; 1995 Jul; 76(2):71A-75A. PubMed ID: 7604803
[TBL] [Abstract][Full Text] [Related]
20. Lipid-lowering therapy with fluvastatin inhibits oxidative modification of low density lipoprotein and improves vascular endothelial function in hypercholesterolemic patients.
Inoue T; Hayashi M; Takayanagi K; Morooka S
Atherosclerosis; 2002 Feb; 160(2):369-76. PubMed ID: 11849660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]